Mylan (MYL) EpiPen Situation 'Far from Over', Wells Fargo's Maris Says
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Wells Fargo analyst David Maris weighed in on Mylan (NASDAQ: MYL) after a CMS spokesperson was quoted by CNBC that, "CMS has, on multiple occasions, provided guidance to the industry and Mylan on the proper classification of drugs, and has expressly advised Mylan that their classification of EpiPen for the purposes of the Medicaid Drug Rebate Program was incorrect." In addition, CNBC cites the Minnesota state health department as estimating this misclassification may have cost Minnesota $4.3 million so far this year.
Maris said if this is true and indicative of the relative costs at other states, they believe the misclassification could be sizable for Mylan, as Minnesota represents less than 2% of the U.S. population.
The analyst expects next steps will be Mylan’s submission of data and information to the panel’s request (this week), and potentially other hearings in the months to come. They are keeping October 12th circled as they expect the Senators will hear from the U.S. Attorney by then.
Maris said they are not aware of Mylan having reaffirmed earnings guidance since this issue has broken out, so are uncertain whether 2016 still stands, although since the EpiPen generic has not been launched, they do not know why it would not still be
The analyst said they continue to believe the EpiPen situation is "far from over with Mylan and represents a risk to the shares."
The firm maintained a Market Perform rating and $43-$45 valuation range.
Shares of Mylan closed at $40.22 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA/Merrill Lynch Upgrades CF Industries (CF) to Buy, Says "Consensus Estimates Now Beatable"
- UPDATE: SunTrust Robinson Humphrey Upgrades UDR, Inc. (UDR) to Buy
- PacWest Bancorp (PACW) PT Raised to $60.50 at FIG Partners Following 4Q Report
Create E-mail Alert Related CategoriesAnalyst Comments
Related EntitiesEarnings, Wells Fargo, David Maris
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!